Top Ten most popular articles on Pharmafile this week
pharmafile | November 25, 2016 | News story | Medical Communications |Â Â November, news, pharmaceutical, top 10, top ten, top ten storiesÂ
This week has seen the pharmaceutical industry return to business as usual after the presidential election provided a boost to the industry; there were some shocks in clinical trials, with surprising failures for big companies, and some big acquisitions. Read here to catch up on these stories and the other biggest articles that have been viewed on our website.
10. Pfizer sues Texas agency over leak of drug prices
Pfizer has sued Texas’ Health and Human Services Commission, after it claimed the agency violated state and federal law by releasing its confidential Medicaid rebate information to two state senators.
9. J&J and Genmab’s drug races to second line treatment approval
Janssen and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been approved as a combination therapy for second-line treatment of bone marrow cancer.
8. GSK 18 months ahead of the game with three-drug inhaler
GlaxoSmithKline, alongside its partner Innoviva, have filed a regulatory submission with the FDA for its treatment for chronic obstructive pulmonary disease (COPD).
7. Teva’s drug to replace chemotherapy in acute leukaemia
Teva Pharmaceutical announced that their drug Trisenox has been given approval from the European Commission to become the first line treatment for Acute Promyelocytic Leukaemia (APL) patients in Europe.
6. Novartis in $665 million deal for Selexys
Novartis have confirmed the acquisition of Selexys Pharmaceuticals, after the company received positive results from a Phase II trial.
5. Pfizer set to develop new $200 million site
Pfizer plans to expand its operations in St. Louis, Missouri, by developing a $200 million facility in Chesterfield to increase its focus on R&D.
4. Allergan acquires Chase Pharma in potential $1 billion deal
Allergan announced that it has completed the acquisition of Chase Pharmaceutical Corporation in a deal worth a potential $1 billion.
3. Patient deaths lead Juno Therapeutics to halt trial for second time
Juno Therapeutics has been forced to halt a trial after two participants died following unexpected side-effects of the drugs.
2. Lilly forced to abandon Alzheimer’s drug after failed trial
Lilly announced, in a shock decision, that the results of its ‘Expedition 3’ trial for an experimental Alzheimer’s disease drug meant that they would now be forced to stop developing the drug.
1. Real world evidence: a reality check for pharma?
Matt Fellows examines this promising research practice and how it could revamp the pharma R&D landscape.
Related Content
FlyPharma Europe, Vienna – 23-24 October 2024 conference
Samedan announces that on 23-24 October 2024, their FlyPharma Conference will make a welcome return …
FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products
This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing …
Zumutor’s cancer drug trial cleared by FDA
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …
